Amgen Inc.

Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs has 15.25B shares outstanding.

As of June 30, 2026, Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 490.28, indicating elevated leverage, while an interest coverage ratio of 6.03 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs posted a return on equity (ROE) of 91.47, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.64 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.53, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.60, useful for judging operating efficiency across full business cycles. The company generates approximately 1.24M in revenue per employee across its workforce of 30,625.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.81 indicates how many times Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs recorded 1.54B in income tax expense. That works out to an effective tax rate of 15.01, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.29B, leaving 8.74B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 22, 2026, Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs's stock has gained approximately 80.52% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs generated 38.10B in revenue and converted that into 8.74B in net income, yielding earnings per share of 0.57. EBITDA reached 16.09B, while operating income came in at 11.43B.

As of June 30, 2026, Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs holds 13.99B in cash and equivalents against 57.30B in total debt, resulting in a net debt position of 43.32B. Total book value stands at 11.69B, with working capital of 9.46B providing operational flexibility.

Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs produced 12.48B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.30B in capital expenditures, free cash flow totaled 10.18B - equivalent to 0.67 per share.

Over the twelve months ended June 30, 2026, Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs posted a gross margin of 69.52, reflecting its pricing power and cost economics. The operating margin of 29.99 and net profit margin of 22.95 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs paid dividends of 0.35 per share. The dividend payout ratio of 60.45 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs's most recent stock split took place on January 24, 2024 with a 1:3 split ratio.